**Core tip:** This *de novo* heart transplant (HTx) cohort demonstrated a median peak oxygen consumption (VO~2peak~) level of 19.4 mL/kg per min at 11 ± 1.8 wk post-HTx, which is comparable to what is shown in maintenance HTx recipients. VO~2peak~ in this study was determined by both central and peripheral factors. The strongest predictors were O~2~ pulse, heart rate reserve and muscular exercise capacity. Maximal exercise testing provides valuable information for clinical use and future prognosis and can be safely performed as early as 11 wk post-HTx.

INTRODUCTION
============

Cardiac rehabilitation, including exercise training to improve exercise capacity and health-related quality of life (HRQoL) is recommended after heart transplant (HTx)\[[@B1]\], but there are no clear and specific guidelines for how, how often or at what intensity exercise training should be performed.

Exercise capacity is often severely reduced shortly after HTx with peak oxygen consumption (VO~2peak~) levels reported to be between 9.2 and 19.7 mL/kg per min\[[@B2]-[@B12]\]. However, early measurement of VO~2peak~ is not routine in most centers. VO~2peak~ is the gold standard to objectively assess functional limitation and give an assessment of the integrative physiology involving cardiovascular, pulmonary, muscular, cellular and oxidative systems\[[@B13],[@B14]\]. It has also been reported that VO~2peak~ is a strong predictor for survival in HTx recipients\[[@B15],[@B16]\]. In studies of maintenance HTx patients, VO~2peak~ seems to be determined by both central (chronotropic incompetence, reduced stroke volume and cardiac output, impaired systolic and diastolic function, pulmonary dysfunction) and peripheral factors (diminished skeletal muscular capacity)\[[@B1],[@B17]-[@B19]\]. Other factors, like donor characteristics, diagnosis and deconditioning before transplantation may also be associated with reduced exercise capacity after HTx\[[@B18]\]. However, we have recently reported that the most important variables predicting VO~2peak~ in maintenance HTx patients are mostly of peripheral origin\[[@B20],[@B21]\]. In *de novo* HTx patients, only two studies exist *(n* = 43\[[@B6]\] and *n* = 24\[[@B12]\]), which report limiting factors for VO~2peak.~ These studies indicate that both central and peripheral factors could be involved in the early phase, but the knowledge is scarce and thus, a better understanding of factors that are associated with peak exercise shortly after HTx could guide clinicians and physiotherapist for more individualized therapy and specific exercise recommendations.

We hypothesized that both central and peripheral factors are associated with reduced exercise capacity in *de novo* HTx recipients. In the present study, we performed cardiopulmonary exercise testing (CPET) in a cohort of *de novo* HTx patients with the aim to determine clinical, hemodynamic and peripheral factors that contribute to the reduced exercise capacity.

MATERIALS AND METHODS
=====================

Patients and settings
---------------------

This study was conducted in three centers in Scandinavia (Oslo, Gothenburg and Copenhagen). Altogether, 155 *de novo* HTx patients were assessed for eligibility. Of these, 72 were excluded for various reasons: did not meet inclusion criteria (cognitive issues, physical disabilities, medical complications, language barriers, contagion, no physical therapist available) (*n* = 43); were not motivated (*n* = 15); logistic reasons (*n* = 14). In addition, two were excluded after they had given their consent, one due to medical complications and one withdrawal. A total of 81 patients underwent CPET. The study was approved by the South-East Regional Committee for medical and health research ethics in Norway and the Committee for medical and health research ethics in Sweden and Denmark. The study was conducted in accordance with the recommendations in the Helsinki Declaration.

The current study is based on the baseline data from an ongoing randomized controlled trial (RCT): The High-intensity Interval Training in de novo heart Transplant recipients in Scandinavia (HITTS) study. The design and rationale of this study is described elsewhere\[[@B22]\]. In short, the RCT compares the effect of a 9-mo long two-armed intervention: High-intensity interval training versus moderate intensity continuous training.

Inclusion criteria
------------------

The inclusion criteria were: Clinically stable HTx recipients approximately 8-12 wk after HTx; Age \> 18 years; Both sexes; Receiving immunosuppressive therapy according to local protocols; Patient willing and able to give written informed consent for study participation, and motivated to participate in the study for nine months.

Measurements
------------

The primary endpoint, VO~2peak~, was measured on a treadmill or a bicycle ergometer applying an individualized protocol with an incremental workload until exhaustion\[[@B23]\]. The Norwegian populations were tested on a treadmill, except for four subjects, who could not comply and were tested on a bicycle ergometer. All patients in Sweden and Denmark were tested on a bicycle, which is the customary form for exercise testing in these countries. The variables from the CPET have been described previously\[[@B22]\]. Common heart rate (HR) variables and abbreviations used in this study were: Peak heart rate (HR~peak~); Percentage of age-predicted maximum HR (% HR~max~) = \[(HR~peak~/220 - age) × 100\]; Chronotropic response index (CRI) = (HR~peak~ -HR~rest~)/(220 - age/HR~rest~); Heart rate reserve (HR~reserve~ ) = HR~peak~ - HR~rest~; HR~recovery~ (difference between HR~peak~ and HR after 30 s, 1, 2, 3 and 4 min).

Secondary endpoints
-------------------

Potential variables influencing VO~2peak~, such as lung function, maximum muscle strength and muscular exercise capacity, bioelectrical impedance analysis, echocardiography, blood samples and HRQoL were measured.

Lung function
-------------

Different lung function variables were measured in relation to the CPET, both at rest and during exercise. Spirometry was performed at rest before CPET: Peak expiratory flow (PEF), forced expiratory volume at 1 min (FEV1), forced vital capacity (FVC) during exercise, maximum ventilation (Vmax) and ventilatory efficiency (VE/VCO~2~)\[[@B14]\] were calculated.

Muscle strength and muscular exercise capacity
----------------------------------------------

Muscle strength and muscular exercise capacity in the quadriceps and hamstring muscle groups were measured isokinetically. Five repetitions at an angular velocity of 60°/s were performed when measuring muscle maximal strength. For the muscular exercise capacity, 30 isokinetic contractions at 240°/s were performed. In the analyses, we used the bilateral sum of m. quadriceps and m. hamstrings\[[@B20],[@B22]\].

Bioelectrical impedance analysis
--------------------------------

Bioelectrical impedance is a simple and fairly valid method to measure body composition\[[@B24]\]. In this study, the Tanita (Tanita, Arlington Heights, IL, United States) system was used to measure body fat, body water, muscle mass, bone mass, visceral fat, metabolic age and basal metabolic rate.

Echocardiography
----------------

Standard Doppler-echocardiography was performed by experienced technicians and assessed by cardiologists to determine myocardial size and function.

Biochemistry
------------

All patients underwent blood sampling in the morning in a fasting state. Two EDTA tubes were collected, inverted ten times and immediately placed on ice. Samples were centrifuged within 20 min. Plasma was transferred into four vials and frozen at -80 °C. One serum tube was collected and placed in room temperature for 60 to 120 min for coagulation before centrifugation. The sample was then transferred into two vials and frozen at -80 °C.

Plasma concentrations of N-terminal pro brain natriuretic peptide (NT-proBNP) was determined using an electrochemiluminescence immunoassay on a Modular platform (Roche Diagnostica, Basel, Switzerland), high sensitive C-reactive protein (hs-CRP) levels using a particle-enhanced, high-sensitive immunoturbidimetric assay (hsCRP, Tina-Quant CRP Gen.3), and high-sensitive troponin T (hs-TnT) was measured by electrochemiluminescence immunoassay (hsTnT, Elecsys Troponin T high sensitive, Roche Diagnostics).

HRQoL and symptoms of anxiety and depression
--------------------------------------------

HRQoL was measured with the generic questionnaire short form-36, version 2 (SF-36v2)\[[@B25]\]. The results were transformed into norm-based scores on a standardized scale with a mean of 50 and a standard deviation (SD) of 10\[[@B25]\]. Subscales were aggregated into two sum-scores; physical component summary (PCS) and mental component summary (MCS). Symptoms of anxiety and depression were measured with the Hospital Anxiety and Depression Scale (HADS)\[[@B26]\]. The values were dichotomized using a cut-off score ≥ 8, which was considered to represent symptoms of depression or anxiety.

Statistical analysis
--------------------

All data were analyzed using IBM SPSS, version 23 and version 25.0 (IBM corporation, United States). Continuous data are expressed as mean ± SD or median first quartile (Q1), third quartile (Q3), and categorical data are presented as percentages. Patients were divided by the median VO~2peak~ (mL/kg per min) value into a low-capacity group (≤ 19.4) and a high-capacity group (\> 19.4). Between-group comparisons were performed using two independent samples t or Mann Whitney *U* test. χ^2^ or *F* were used for categorical data, where appropriate. Bivariate relationships were explored and univariate regression analyses were performed with potential predictors (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). To identify the degree of association with VO~2peak,~ all relevant variables with *P* \< 0.05 and other potential variables from the univariate analyses of linear regression were selected for further multiple regression analyses. VO~2peak~ (L/min), adjusted for age, sex and BMI, was used as the dependent variable. The final model was built using a series of multiple regression analyses with the enter method (Table [3](#T3){ref-type="table"}). Assumptions were checked for normality and linearity.

###### 

Clinical characteristics and health-related quality of life of the study population

  **[6](#T1FN6){ref-type="table-fn"}*N* = 55-81**   **Total**               **Low-capacity group** **(*n* = 41)** **VO~2peak~ ≤** **19.4 mL/kg per min**   **High-capacity group** **(*n* = 40)** **VO~2peak~ \>** **19.4 mL/kg per min**   **t** **(*P*-value)**                   **Univariate regression** **Standardized coefficient Beta \[95%CI\], *P*** **VO~2peak~ (L/min)**   **[7](#T1FN7){ref-type="table-fn"}R^2^**
  ------------------------------------------------- ----------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------
  Clinical characteristics                                                                                                                                                                                                                                                                                                                                                             
  Sex (% men)                                       73%                     66                                                                             80                                                                               0.152[1](#T1FN1){ref-type="table-fn"}   -0.45 \[-0.61, -0.23\], \< 0.001                                                                   0.2
  Age (yr)                                          49 ± 13                 51 ± 11                                                                        46 ± 15                                                                          0.08                                    -0.19 \[-0.01, -0.001\], 0.093                                                                     0.04
  Body mass index                                   25.3 ± 3.7              26.3 ± 3.4                                                                     24.2 ± 3.8                                                                       0.01                                    0.28 \[0.007, 0.056\], 0.013                                                                       0.08
  Body fat (%)                                      25.1 ± 8.7              29.0 ± 8.3                                                                     21.0 ± 7.1                                                                       \<0.001                                 -0.34 \[-0.03, -0.006\], 0.003                                                                     0.11
  Donor age (yr)                                    34 (24, 49)             37 (27, 48)                                                                    33 (23, 52)                                                                      0.825[2](#T1FN2){ref-type="table-fn"}   0.09 \[-0.004, 0.009\], 0.447                                                                      0.01
  Ischemic time (min)                               210 (95, 237)           215 (99, 249)                                                                  185 (87, 227)                                                                    0.072[2](#T1FN2){ref-type="table-fn"}   -0.01\[-0.001, 0.001\], 0.938                                                                      8.2^-5^
  Weeks after HTx                                   11 ± 1.8                11.3 ± 2                                                                       10.9 ± 1.5                                                                       0.307                                   -0.001 \[-0.05, 0.05\], 0.990                                                                      2.0^-5^
  Duration of HF prior to HTx (yr)                  4 (1.5, 10)             4 (1.5, 10.5)                                                                  4 (1.0, 9.3)                                                                     0.718[2](#T1FN2){ref-type="table-fn"}   -0.05 \[-0.02, 0.01\], 0.681                                                                       0.002
  Time on HTx waiting list (d)                      75 (24, 193)            96 (29, 227)                                                                   47 (12, 131)                                                                     0.06[2](#T1FN2){ref-type="table-fn"}    -0.14 \[-0.001, 1.5-4\], 0.202                                                                     0.02
  Rejections grade 1-2 (% yes)                      45                      48                                                                             43                                                                               0.653[1](#T1FN1){ref-type="table-fn"}   0.09 \[-0.11, 0.27\], 0.408                                                                        0.01
  VO~2peak~ preHTx (mL/kg per min)                  11.6 ± 3.3              11.1 ± 3                                                                       12.1 ± 3.5                                                                       0.248                                   0.03 \[-0.032, 0.039\], 0.826                                                                      0.001
  LVAD (% yes)                                      15                      22                                                                             8                                                                                0.067[1](#T1FN1){ref-type="table-fn"}   -0.14 \[-0.43, 0.097\], 0.211                                                                      0.02
  Preoperative IABP/ECMO (% yes)                    16                      15                                                                             18                                                                               0.725[1](#T1FN1){ref-type="table-fn"}   0.05 \[-0.20, 0.32\], 0.637                                                                        0.003
  Postoperative IABP/ECMO (% yes)                   10                      15                                                                             5                                                                                0.264[3](#T1FN3){ref-type="table-fn"}   -0.26 \[-0.68, -0.066\], 0.018                                                                     0.07
  Etiology HF (%)                                                                                                                                                                                                                           0.138[3](#T1FN3){ref-type="table-fn"}                                                                                                      
  Cardiomyopathy                                    65                      56                                                                             75                                                                                                                                                                                                                          
  Ischemic heart disease                            25                      34                                                                             15                                                                                                                                                                                                                          
  Other                                             10                      10                                                                             10                                                                                                                                                                                                                          
  Smoking (%) no/yes/ex-smoker                      49/0/51                 34/0/66                                                                        65/0/35                                                                          0.005[1](#T1FN1){ref-type="table-fn"}   -0.19 \[-0.34, 0.03\], 0.100                                                                       0.03
  24 h ambulatory blood pressure                                                                                                                                                                                                                                                                                                                                                       
  Overall systolic BP                               133 ± 12                133 ± 13                                                                       132 ± 10                                                                         0.672                                                                                                                                      
  Overall diastolic BP                              81 ± 7                  80 ± 8                                                                         82 ± 7                                                                           0.493                                                                                                                                      
  Medication (%)                                                                                                                                                                                                                                                                                                                                                                       
  Ciclosporin                                       70                      63                                                                             78                                                                               0.165[1](#T1FN1){ref-type="table-fn"}                                                                                                      
  Tacrolimus                                        28                      32                                                                             23                                                                               0.352[1](#T1FN1){ref-type="table-fn"}                                                                                                      
  Everolimus                                        34                      43                                                                             25                                                                               0.098[1](#T1FN1){ref-type="table-fn"}                                                                                                      
  Mycophenolate                                     90                      81                                                                             100                                                                              0.005[3](#T1FN3){ref-type="table-fn"}   0.29 \[0.10, 0.71\], 0.009                                                                         0.08
  Prednisolone                                      100                     100                                                                            100                                                                                                                                                                                                                         
  Beta-blocker                                      28                      40                                                                             15                                                                               0.012[1](#T1FN1){ref-type="table-fn"}   -0.19 \[-0.39, -0.03\], 0.086                                                                      0.04
  Calcium blocker                                   25                      25                                                                             25                                                                               1.000[1](#T1FN1){ref-type="table-fn"}                                                                                                      
  ACE inhibitors                                    3                       3                                                                              3                                                                                1.000[3](#T1FN3){ref-type="table-fn"}                                                                                                      
  AII-blocker                                       9                       13                                                                             5                                                                                0.263[3](#T1FN3){ref-type="table-fn"}                                                                                                      
  Diuretics                                         79                      80                                                                             78                                                                               0.785[1](#T1FN1){ref-type="table-fn"}                                                                                                      
  Statins                                           99                      98                                                                             100                                                                              1.000[3](#T1FN3){ref-type="table-fn"}                                                                                                      
  Blood samples                                                                                                                                                                                                                                                                                                                                                                        
  TG (mmol/L)                                       1.7 (1.3, 2.5)          2.1 (1.5, 2.8)                                                                 1.5 (1.1, 2.2)                                                                   0.013[2](#T1FN2){ref-type="table-fn"}   -0.24 \[-0,19, -0.002\], 0.045                                                                     0.06
  LDL (mmol/L)                                      2.9 ± 1.0               3.0 ± 1.2                                                                      2.9 ± 0.7                                                                        0.416                                   0.12 \[-0.05, 0.15\], 0.308                                                                        0.01
  HDL (mmol/L)                                      1.5 ± 0.5               1.5 ± 0.5                                                                      1.6 ± 0.5                                                                        0.432                                   0.04 \[-0.16, 0.22\], 0.755                                                                        0.001
  Cholesterol (mmol/L)                              5.1 ± 1.3               5.3 ± 1.5                                                                      5.0 ± 1.0                                                                        0.329                                   0.03 \[-0.07, 0.09\], 0.830                                                                        0.001
  Hemoglobin (g/dL)                                 11.8 ± 1.7              11.3 ± 1.9                                                                     12.2 ± 1.4                                                                       0.017                                   0.38 \[0.042, 0.15\], 0.001                                                                        0.14
  hs-CRP (mg/L)                                     2.3 (1.0, 6.1)          2.7 (1.3, 6.7)                                                                 1.6 (0.6, 3.9)                                                                   0.052[2](#T1FN2){ref-type="table-fn"}   -0.17 \[-0.015, 0.002\], 0.125                                                                     0.03
  NT-proBNP (ng/L)                                  968.3 (625.8, 1680.8)   1348.9 (765.4,2006.4)                                                          790.7 (522.2, 1351.0)                                                            0.005[2](#T1FN2){ref-type="table-fn"}   -0.36\[-2.7E-4, -6.5^-5^\], 0.002                                                                  0.13
  hs-TnT (ng/L)                                     32.5 (20.0, 61.8)       42.0 (27.8, 66.7)                                                              24.0 (18.0, 50.8)                                                                0.009[2](#T1FN2){ref-type="table-fn"}   -0.18 \[-0.005, 0.001\], 0.128                                                                     0.03
  HbA1c (%)                                         5.6 ± 0.8               5.8 ± 0.9                                                                      5.4 ± 0.7                                                                        0.038                                   -0.15 \[-0.19, 0.04\], 0.213                                                                       0.02
  Glucose (mmol/L)                                  5.9 ± 1.8               6.3 ± 2.1                                                                      5.5 ± 1.4                                                                        0.046                                   -0.19 \[-0.1, 0.01\], 0.109                                                                        0.04
  Leukocytes (× 10^-9^/L)                           5.4 ± 2.3               6.0 ± 2.7                                                                      4.7 ± 1.6                                                                        0.017                                   -0.06 \[-0.05, 0.03\], 0.580                                                                       0.004
  Creatinine (μmol/L)                               117.4 ± 31.4            118.0 ± 31.9                                                                   116.9 ± 31.3                                                                     0.868                                   -0.05 \[-0.004, 0.002\], 0.669                                                                     0.002
  Carbamide (mmol/L)                                9.8 ± 3.4               9.9 ± 4.0                                                                      9.7 ± 2.7                                                                        0.865                                   -0.003 \[-0.03, 0.03\], 0.977                                                                      1.00E-05
  eGFR (mL/min per 1.73 m^2^)                       55 ± 16                 54.1 ± 17.0                                                                    56.1 ± 15.0                                                                      0.586                                   0.23 \[3.9E-5,0.01\], 0.049                                                                        0.05
  Muscle strength and muscular exercise capacity                                                                                                                                                                                                                                                                                                                                       
  Muscle strength (Nm)                              279 ± 129               231 ± 128                                                                      326 ± 113                                                                        0.001                                   0.66 \[0.002, 0.003\], \< 0.001                                                                    0.43
  Muscular Exercise capacity (J)                    3229 ± 1660             2423 ± 1351                                                                    4015 ± 1567                                                                      \< 0.001                                0.64 \[0.0001, 0.0002\], \< 0.001                                                                  0.41
  Spirometry                                                                                                                                                                                                                                                                                                                                                                           
  FEV1 (%)                                          81 ± 16                 74 ± 14                                                                        88 ± 16                                                                          \< 0.001                                0.39 \[0.004, 0.02\], 0.001                                                                        0.16
  PEF (%)                                           85 ± 22                 79 ± 23                                                                        91 ± 20                                                                          0.018                                   0.37 \[0.003, 0.01\], 0.001                                                                        0.14
  FVC (%)                                           86 ± 17                 81 ± 16                                                                        90 ± 16                                                                          0.026                                   0.17 \[-0.002, 0.01\], 0.152                                                                       0.03
  Echocardiography                                                                                                                                                                                                                                                                                                                                                                     
  EF (%)                                            57.9 ± 5.6              56.2 ± 5.4                                                                     59.4 ± 5.4                                                                       0.011                                   0.26 \[0.003, 0.04\], 0.025                                                                        0.07
  LVEDD (cm)                                        4.9 ± 0.5               4.9 ± 0.5                                                                      4.9 ± 0.4                                                                        0.996                                   0.42 \[0.19, 0.59\], \< 0.001                                                                      0.18
  FS (%)                                            36.7 ± 5.9              35.9 ± 6.8                                                                     37.5 ± 4.9                                                                       0.242                                   0.23 \[-4.7E-5, 0.03\], 0.051                                                                      0.05
  CO (L/min)                                        6.1 ± 1.2               6.0 ± 1.2                                                                      6.2 ± 1.2                                                                        0.467                                   0.39 \[0.06, 0.21\], 0.001                                                                         0.15
  Health-related quality of life                                                                                                                                                                                                                                                                                                                                                       
  PCS                                               43 ± 8                  41 ± 7                                                                         45 ± 8                                                                           0.029                                   0.35 \[0.008, 0.03\], 0.001                                                                        0.13
  MCS                                               54 ± 11                 53 ± 10                                                                        55 ± 11                                                                          0.416                                   0.17 \[-0.002, 0.02\], 0.127                                                                       0.03
  Symptoms of anxiety and depression                                                                                                                                                                                                                                                                                                                                                   
  HADS-A ≥ 8 (%)[4](#T1FN4){ref-type="table-fn"}    15                      17                                                                             13                                                                               0.562[1](#T1FN1){ref-type="table-fn"}   -0.26 \[-0.56, -0.05\], 0.02                                                                       0.07
  HADS-D ≥ 8 (%)[5](#T1FN5){ref-type="table-fn"}    5                       5                                                                              5                                                                                1.000[3](#T1FN3){ref-type="table-fn"}   -0.16 \[-0.73, 0.13\], 0.165                                                                       0.03

Groups are divided according to the median VO~2peak~ (mL/kg per min). Variables are presented as percentages, mean ± SD or as median (Q1, Q3) where appropriate.

χ^2^;

Mann Whitney U-test;

F;

HADS-A score ≥ 8 indicates symptoms of anxiety;

HADS-D score ≥ 8 indicates symptoms of depression;

The actual N varies from 55 to 81 for different variables;

Unadjusted *R*^2^. ACE: Angiotensin-converting enzyme; ATII: Angiotensin II; BP: Blood pressure; CO: Cardiac output; ECMO: Extracorporeal membrane oxygenation; EF: Ejection fraction; FEV~1~: Forced expiratory volume at 1 min; FVC: Forced vital capacity; FS: Fractional shortening; HADS: Hospital anxiety and depression scale; HbA1c: Hemoglobin A1c; HDL: High density lipoprotein; hs-CR: High-sensitive C-reactive protein; hs-TnT: High-sensitive troponin T; HTx: Heart transplantation; IABP: Intra-aortic balloon pump; LVAD: Left ventricle assist device; LVEDD: Left ventricular end diastolic diameter; MCS: Mental component summary; Nm: Newton meter; NT-pro BNP: N-terminal pro brain natriuretic peptide; PEF: Peak expiratory flow; PCS: Physical component summary; Q1: First quartile; Q3: Third quartile; SD: Standard deviation; TG: Triglyceride.

###### 

Cardiopulmonary responses to exercise of the study population

  **[2](#T2FN2){ref-type="table-fn"}*N* = 63-81**   **Total**          **Low-capacity group** **VO~2peak~ ≤ 19.4 mL/kg per min (*n* = 41)**   **High-capacity group** **VO~2peak~ \> 19.4 mL/kg per min (*n* = 40)**   **t** **(*P*-value)**                   **Univariate regression** **Standardized coefficient** **Beta \[95%CI\], *P*** **VO~2peak~ L/min**   **[3](#T2FN3){ref-type="table-fn"}R^2^**
  ------------------------------------------------- ------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------
  VO~2peak~ (mL/kg per min)                         20.4 ± 4.9         16.4 ± 2                                                               24.3 ± 3.6                                                               \< 0.001                                0.75 \[0.05, 0.08\], \< 0.001                                                                        0.56
  VO~2peak~ (L/min)                                 1.6 ± 0.4          1.3 ± 0.3                                                              1.8 ± 0.4                                                                \< 0.001                                                                                                                                     
  %expected VO~2peak~                               55.8 ± 12.4        46.5 ± 7.4                                                             65.3 ± 8.6                                                               \< 0.001                                0.60 \[0.01, 0.03\], \< 0.001                                                                        0.36
  RER                                               1.2 ± 0.1          1.2 ± 0.14                                                             1.2 ± 0.10                                                               0.898                                                                                                                                        
  HRrest (echocardiography)                         87 ± 10            87 ± 11                                                                86 ± 9                                                                   0.85                                    -0.07 \[-0.013, 0.007\], 0.551                                                                       0.01
  Peak systolic BP (mmHg)                           188 ± 30           188 ± 31                                                               189 ± 30                                                                 0.865                                   0.19 \[-0.001, 0.006\], 0.108                                                                        0.04
  Peak diastolic BP (mmHg)                          82 ± 17            82 ± 18                                                                82 ± 16                                                                  0.917                                   0.09 \[-0.004, 0.008\], 0.467                                                                        0.01
  VE/VCO~2slope~                                    34.8 ± 7.7         37.3 ± 7.2                                                             32.6 ± 7.6                                                               0.008                                   -0.42 \[-0.035, -0.01\], \< 0.001                                                                    0.18
  Vmax (L)                                          71.4 ± 22.8        60.5 ± 17.5                                                            81.7 ± 22.7                                                              \< 0.001                                0.76\[0.01, 0.02\], \< 0.001                                                                         0.58
  O~2~ pulse (mL/beat)                              12.4 ± 3.3         11.0 ± 3                                                               13.7 ± 3                                                                 \< 0.001                                0.80 \[0.08, 0.12\], \< 0.001                                                                        0.65
  AT (L/min)                                        1.08 ± 0.3         0.95 ± 0.2                                                             1.2 ± 0.3                                                                0.001                                   0.73 \[0.74, 1.2\], \< 0.001                                                                         0.53
  METS                                              6.5 ± 1.6          5.4 ± 0.8                                                              7.8 ± 1.3                                                                \< 0.001                                0.77 \[0.16, 0.24\], \< 0.001                                                                        0.59
  HRpeak (beats/min)                                128 ± 19           121 ± 19                                                               134 ± 17                                                                 0.001                                   0.31 \[0.002, 0.01\], 0.005                                                                          0.1
  %HRmax                                            75 ± 12            72 ± 12                                                                78 ± 11                                                                  0.021                                   0.20 \[-0.001, 0.02\], 0.071                                                                         0.04
  HRreserve (beats/min)                             43 ± 16            35 ± 13                                                                50 ± 15                                                                  \< 0.001                                0.47 \[0.01, 0.02\], \< 0.001                                                                        0.22
  CRI                                               0.51 ± 0.2         0.45 ± 0.18                                                            0.57 ± 0.2                                                               0.004                                   0.31 \[0.20, 1.12\], 0.005                                                                           0.1
  RPE (Borg scale)                                  18.6 ± 0.8         18.5 ± 1                                                               18.6 ± 0.5                                                               0.638                                                                                                                                        
  Test duration (min)                               9.5 ± 2.8          7.8 ± 1.5                                                              11.1 ± 2.7                                                               \< 0.001                                                                                                                                     
  HRrecovery                                                                                                                                                                                                                                                                                                                                                        
  Beats /min at 2 min                               -1.0 (-3.0, 1.0)   -1.0 (-3.0, 1.0)                                                       -2.0 (-3.3, 1.3)                                                         0.697[1](#T2FN1){ref-type="table-fn"}                                                                                                        

Groups are divided according to the median VO~2peak~ (mL/kg per min). Variables are presented as mean ± SD or as median (Q1, Q3) where appropriate.

Mann Whitney *U*-test;

The actual N varies from 63 to 81 for different variables;

Unadjusted R^2^. BP: Blood pressure; CI, confidence interval; CRI, chronotropic response index; HR, heart rate; METS, metabolic equivalents; Vmax, maximum ventilation; Q1, first quartile; Q3, third quartile; RER, Respiratory Exchange Ratio; RPE, rated perceived exertion; SD, standard deviation.

###### 

Multiple regression analysis

  ***N* = 66**                         **Model 1** **Standardized coefficient Beta \[95% CI\]**   ***P*-value**   **Model 2** **Standardized coefficient Beta \[95% CI\]**   ***P*-value**
  ------------------------------------ ---------------------------------------------------------- --------------- ---------------------------------------------------------- ---------------
  O~2~ pulse (mL/beat)                 0.707 \[0.075, 0.104\]                                     \< 0.001        0.675 \[0.069, 0.102\]                                     \< 0.001
  HRreserve (beats/min)                0.382 \[0.007, 0.013\]                                     \< 0.001        0.397 \[0.008, 0.013\]                                     \< 0.001
  Muscular exercise capacity (Joule)   0.162 \[1.1E-5, 7.1E-5\]                                   0.008           0.155 \[8.0^-5^, 7.1^-5^\]                                 0.015
  BMI (kg/m^2^)                                                                                                   0.067 \[-0.004, 0.020\]                                    0.211
  Sex                                                                                                             -0.029 \[-0.142, 0.086\]                                   0.630
  Age (yr)                                                                                                        0.019 \[-0.003, 0.004\]                                    0.719
  Adjusted *R*^2^                      0.85                                                                       0.84                                                       

Dependent variable VO~2peak~ L/min. Final model for *n* = 66. BMI: Body mass index; CI: Confidence interval; HR: Heart rate.

RESULTS
=======

Clinical characteristics
------------------------

The mean ± SD age of the total study population was 49 ± 13 years, and 73% were men. Patients were on average 11.1 ± 1.8 wk after HTx. The mean VO~2peak~ was 20.4 mL/kg per min, which is 56% of expected compared to the reference values described in the 9^th^ edition of the American College of Sports Medicine's (ACSM) guidelines for exercise testing and exercise prescription\[[@B27]\]. Further demographic and clinical characteristics are presented group-wise in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

Compared to the high-capacity group, the low-capacity group was characterized by a higher body mass index (BMI) and a higher fat content, they were more often ex-smokers, had lower PCS score, had less muscle strength and muscular exercise capacity, had lower FEV1, FVC and ejection fraction (EF) as measured by echocardiography. The low-capacity group more often used beta blockers and less mycophenolate, had higher NT-proBNP, hs-TnT, triglycerides and lower hemoglobin (Hgb). Duration of heart failure before HTx, primary diagnosis, donor age, ischemic time, rejection scores, MCS score and HADS depression score were similar between the two groups (Table [1](#T1){ref-type="table"}).

Exercise variables
------------------

Exercise variables are shown in Table [2](#T2){ref-type="table"}. As compared with the high-capacity group, the low-capacity group exercised for a shorter time, had lower maximal ventilation, O~2~ pulse, HR~peak~ and HR~reserve~, while VE/VCO~2~ slope was higher (Table [2](#T2){ref-type="table"}). The respiratory exchange ratio (RER), rated perceived exertion (RPE) and blood pressure responses were similar between the groups (Table [2](#T2){ref-type="table"}).

Predictors of VO~2peak~
-----------------------

Univariate predictors of VO~2peak~ are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. There were strong correlations (*P* \< 0.001) between VO~2peak~ and HR~reserve~, O~2~ pulse and muscular exercise capacity (Figures [1](#F1){ref-type="fig"}-[](#F2){ref-type="fig"}[3](#F3){ref-type="fig"}). In multiple regression analyses, O~2~ pulse, HR~reserve~, muscular exercise capacity, BMI, gender and age accounted for 84% of the variance in VO~2peak~ (L/min). Only O~2~ pulse, HR~reserve~ and muscular exercise capacity were important determinants in the final model (*P* \< 0.001, *P* \< 0.001 and *P* \< 0.015, respectively). Other potential predictors were also analyzed in the multiple regression analyses, but these did not reach statistical significance. VO~2peak~ (L/min) was chosen as the dependent variable in order to be able to adjust for and see the impact of age, gender and BMI directly, as the VO~2peak~ (mL/kg per min) variable is already weight-based.

![Scatterplot of the correlation between peak oxygen consumption (L/min) and heart rate reserve with inserted regression line. *R*^2^ = 0.224. Pearsons *r* 0.473, *P* \< 0.001. VO~2peak~: Peak oxygen consumption; HR~reserve~: Heart rate reserve.](WJT-8-188-g001){#F1}

![Scatterplot of the correlation between peak oxygen consumption (L/min) and O2 pulse with inserted regression line. *R*^2^ = 0.647. Pearsons *r* 0.804, *P* \< 0.001. VO~2peak~: Peak oxygen consumption.](WJT-8-188-g002){#F2}

![Scatterplot of the correlation between peak oxygen consumption (L/min) and muscular exercise capacity (Joule) with inserted regression line. *R*^2^ = 0.406. Pearsons *r* 0.637, *P* \< 0.001. VO~2peak~: Peak oxygen consumption.](WJT-8-188-g003){#F3}

Safety
------

All measurements performed in this study, including the CPET and muscle strength testing, were completed without any minor or serious adverse events.

DISCUSSION
==========

The main findings in this study were that *de novo* HTx patients display reduced exercise capacity compared with a general population: The reference population in ACSM\[[@B27]\] and Astrand\[[@B28]\], and that maximal exercise capacity was determined by both central (O~2~ pulse and HR~reserve~) and peripheral factors (muscular exercise capacity) (Table [3](#T3){ref-type="table"} and Figures [1](#F1){ref-type="fig"}-[3](#F3){ref-type="fig"}). Furthermore, CPET can be safely performed as early as an average of 11 wk after HTx and is a valuable basis for individual tailoring of the further rehabilitation program.

In addition to the main predictors mentioned above, self-reported physical function was also positively associated with VO~2peak~ in this cohort, which is in accordance with an earlier paper from our research team\[[@B15]\]. Similar findings are reported from the general population in the Norwegian HUNT study, in which physical activity level was associated with VO~2peak~\[[@B29]\]. Although both groups in our current study had a lower score on the physical function subscale compared to the norm values described in Ware et al\[[@B25]\], the high-capacity group had a clinical meaningful and significantly higher score than the low-capacity group on physical function. The high-capacity group also had higher score on the PCS. On the other hand, there were no differences between the two groups regarding the psychosocial subscales or MCS in SF-36v2.

As previously mentioned, only two previous studies exist that describe determinants for VO~2peak~ in *de novo* HTx recipients\[[@B6],[@B12]\]. Kitagaki et al\[[@B6]\] found that knee extensor muscle strength and cholinesterase were important predictors for VO~2peak~ 55 d after surgery. Salyer et al\[[@B12]\] found that age was the only predictor of VO~2\ peak~ 68 d after HTx, but they did not include muscular exercise capacity or chronotropic variables in their regression analyses. A small study (*n* = 15) by Oliveira Carvalho et al\[[@B30]\] described that HR~reserve~, as the only important variable, was associated with VO~2peak~ six months after HTx, while in maintenance HTx recipients, HR~reserve~ was no longer strongly associated with VO~2peak~. In HR~recovery~ after exercise, there was an important difference between early and late HTx recipients, suggesting a partial reinnervation in maintenance HTx recipients\[[@B30]\]. However, peripheral factors such as muscular exercise capacity were not measured in Oliveira Carvalho's study\[[@B30]\]. Borelli et al\[[@B31]\] followed HTx recipients for two years and found that both central and peripheral factors contributed to the reduced VO~2peak~ both early (5.3 mo) and late (2 years) after HTx, but that the improvements in VO~2peak~ seen over two years were mostly related to peripheral factors.

In the present study, both HR~reserve~ and O~2~ pulse were independent predictors of VO~2peak~. The chronotropic responses, CRI, %HR~max~ and HR~peak~ were, as expected, lower than normal both in the low-capacity and the high-capacity group. However, the high-capacity group had better chronotropic responses than the low-capacity group (CRI, *P* = 0.004; %HR~max~, *P* = 0.021, HR~peak~, *P* = 0.001; HR~reserve~, *P* \< 0.001). HR~recovery~ was markedly delayed in both groups, with no difference between the groups. Previous studies in maintenance HTx recipients have reported conflicting results whether chronotropic incompetence is associated with a reduced VO~2peak~ or not. Schwaiblmair et al\[[@B32]\] and Kemp et al\[[@B33]\] found a higher VO~2peak~ in patients with a greater HR~reserve,~ compared to patients with a lower HR~reserve.~ In contrast, Squires et al\[[@B34]\] found no difference in VO~2peak~ between patients with high versus low HR~reserve~ (46 ± 15 *vs* 33 ± 15). In a previous study by our research group, where maintenance HTx recipients demonstrated a close to normal chronotropic response, HR~reserve~ was not a strong determinant of VO~2peak~\[[@B20]\]. However, in this current study of *de novo* HTx recipients, it is (Figure [1](#F1){ref-type="fig"}). The findings described above suggest that as the initially impaired chronotropic responses improve over time, they become less predictive of VO~2peak~.

O~2~ pulse derived from CPET is considered a surrogate for stroke volume\[[@B14],[@B35],[@B36]\]. In the current study, there was a strong correlation between VO~2\ peak~ and O~2~ pulse (Figure [2](#F2){ref-type="fig"}). In line with this, the high-capacity group also had a higher O~2~ pulse (*P* \< 0.001), increased left ventricular EF, as well as lower NT-proBNP and hs-TnT levels, reflecting a better preserved myocardial function compared with the low-capacity group.

*De novo* HTx recipients have reduced muscle mass mostly due to inactivity prior to HTx\[[@B18]\]. The high-capacity group had higher muscular exercise capacity (*P* \< 0.001) and muscular strength (*P* = 0.001) than the low-capacity group (Figure [3](#F3){ref-type="fig"}), and this finding supports the previously described association between muscle function and VO~2peak~\[[@B20]\]. Comparing the muscle strength values from our previous study on maintenance recipients\[[@B20]\] with the values in this current study, they are not surprisingly much lower in the *de novo* recipients. As muscular exercise capacity is the only peripheral predictor for VO~2\ peak~ in the current study, peripheral factors might be less dominant than central factors in the early phase after HTx. However, from a clinical point of view, resistance training in the early rehabilitation after HTx is of high importance in order to prevent and restore loss of muscle mass and bone density and is likely to contribute to an improved VO~2peak~ level\[[@B37]\].

In the existing literature, VO~2peak~ in *de novo* HTx patients is reported to range from 9.2 mL/kg per min up to 19.7 mL/kg per min (1-3 mo after HTx)\[[@B2]-[@B12]\]. One small study of nine patients with left ventricle assist device (LVAD) prior to HTx had a mean VO~2peak~ of 24.6 mL/kg per min 12 wk after HTx, which is higher than what has been reported in other studies and may be explained by the LVAD effect and the patients' relatively high VO~2peak~ before HTx\[[@B38]\]. Except for this study, our cohort's mean VO~2peak~ level of 20.4 mL/kg per min (measured 11 wk post HTx) is higher than what is previously reported in *de novo* HTx recipients. Compared to an earlier exercise study in maintenance HTx recipients from our center with a median VO~2peak~ value of 27.3 mL/kg per min\[[@B20]\], this *de novo* HTx cohort is below this value, but compared to other international studies in maintenance HTx recipients, our current *de novo* HTx recipients are close to these reported values\[[@B18]\]. This may be partially related to the early and individualized exercise program conducted at our centers, where the patients are attended to daily by a physical therapist from the multidisciplinary HTx team.

Results from a CPET test can be important in many aspects in the early phase after HTx. First of all, a maximal exercise test is of great value to the individual patient in terms of contributing to increased confidence in their new heart and the body's tolerance to high-intensity exercise. Secondly, an early CPET is useful for deciding and tailoring the individual exercise programs and for the further rehabilitation, both for monitoring patients' status and prognosis and measuring effect of exercise. In addition to the many gas exchange variables, the CPET also provides other valuable and useful measurements, such as lung function and chronotropic responses. Finally, as we know that measures of physical capacity are strong predictors for long-term survival in HTx recipients\[[@B15],[@B16]\], we suggest that such measures should be routinely included both in the early phase after HTx and at yearly controls thereafter. We underscore that the safety aspect is very important when performing a CPET and it should always be supervised by competent and experienced health personnel.

Limitations
-----------

Selection bias is a common risk in all voluntary studies, and although our aim was to include every newly transplanted HTx recipient, the recipients had to be medically stable and able to perform a maximal CPET and other physical tests. Thus, as the median VO~2peak~ value in this *de novo* cohort is comparable to maintenance HTx recipients' VO~2peak~ values, this may be due to a possible selection bias.

This is a cross-sectional study, based on the baseline data from an ongoing RCT, and no causal relationships should be drawn from such a study design. We present only associations between VO~2peak~ and different possible determinants. A rather small sample size (*n* = 81) may also imply type 2 errors, but all the performed statistics were carefully checked for underlying assumptions.

In this *de novo* HTx cohort, the age-predicted mean VO~2\ peak~ value was 56% of age-expected values, which is comparable to previously reported values in maintenance HTx\[[@B18]\]. Predictors for VO~2peak~ in *de novo* HTx recipients seem to be of both central (O~2~ pulse and HR~reserve~) and peripheral (muscular exercise capacity) origin. A CPET and determination of muscular exercise capacity provide important information for patient motivation, rehabilitation and prognosis and thus, measurements for physical function should be considered as routine examinations early after HTx.
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ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Peak oxygen consumption (VO~2peak~) is reduced after heart transplant (HTx). Both peripheral and central factors are determinants of the reduced VO~2peak~ in maintenance HTx recipients, but there are still few studies among *de novo* HTx patients. A higher VO~2peak~ is associated with better prognosis after HTx, and knowledge about predictors for VO~2peak~ in *de novo* HTx is important for the rehabilitation process. A cardiopulmonary exercise test (CPET) is the gold standard for measuring VO~2peak~ and should be performed as a routine test early after HTx.

Research motivation
-------------------

More knowledge about predictors for VO~2peak~ in *de novo* HTx patients may contribute to a better understanding of the reduced exercise capacity early after HTx. Individualized exercise prescriptions are very important after HTx, and a CPET early after HTx will guide both clinicians and physiotherapists in this vulnerable phase of the rehabilitation process.

Research objectives
-------------------

The aim of this study was to investigate determinants of early VO~2peak~ and exercise capacity in a cohort of *de novo* HTx recipients.

Research methods
----------------

This study used baseline data from an ongoing randomized controlled trial investigating high-intensity interval training compared to moderate continuous exercise training among *de novo* HTx recipients, the HITTS study. A cross sectional analysis was performed on the baseline data from the 81 patients included in the study, and all baseline tests were performed an average of 11 wk after surgery. The primary endpoint was VO~2peak~ measured by CPET. Secondary endpoints were lung function, maximum muscle strength and muscular exercise capacity, bioelectrical impedance analysis, echocardiography, blood samples and health-related quality of life.

Research results
----------------

The main findings in this study were that *de novo* HTx patients display reduced exercise capacity compared to a general population, but comparable with maintenance HTx recipients. This *de novo* HTx cohort demonstrated a median VO~2peak~ level of 19.4 mL/kg per min at 11 ± 1.8 wk post-HTx. Maximal exercise capacity was determined by both central (O~2~ pulse and HR~reserve~) and peripheral factors (muscular exercise capacity). The CPET tests were performed without any serious adverse events mean 11 wk after HTx. This is a cross-sectional study, and no causal relationships should be drawn from such a study design. We present only associations between VO~2peak~ and different possible determinants.

Research conclusions
--------------------

In this *de novo* HTx cohort, the age-predicted mean VO~2\ peak~ value was 56% of age-expected values, which is comparable to previously reported values in maintenance HTx. Predictors for VO~2peak~ in *de novo* HTx recipients seem to be of both central and peripheral origin.

Research perspectives
---------------------

A CPET and determination of muscular exercise capacity provide important information for patient motivation, rehabilitation and prognosis and thus, measurements for physical function should be considered as routine examinations early after HTx.
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